Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
暂无分享,去创建一个
P. Merlet | H. Cavé | L. Sarda-Mantel | P. Fenaux | L. Adès | N. Setterblad | M. Fontenay | M. Pla | F. Hervatin | A. Janin | C. Chomienne | N. Omidvar | O. Kosmider | C. Leboeuf | B. Cassinat | R. Padua | Stéphanie Beurlet | C. le Pogam | M. Noguera | P. Krief | A. Soulié | N. Balitrand
[1] M. Morgan,et al. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas , 2013, Oncogene.
[2] M. Konopleva,et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex , 2012, Leukemia.
[3] D. Green,et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.
[4] M. Eberl,et al. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL , 2011, Breast Cancer Research.
[5] B. Goh,et al. The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity. , 2011, Blood.
[6] J. Wright,et al. A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia , 2011, Leukemia.
[7] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[8] M. Jädersten,et al. Myelodysplastic syndromes: biology and treatment , 2009, Journal of internal medicine.
[9] B. Smith,et al. Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features , 2008, Clinical Cancer Research.
[10] I. Weissman,et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. , 2007, Cancer research.
[11] G. Mufti,et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? , 2007, Cancer research.
[12] G. Mufti,et al. Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis? , 2006, Molecular Cancer Research.
[13] A. Burnett,et al. Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras , 2006, Molecular and Cellular Biology.
[14] C. Thompson,et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. , 2006, Molecular cell.
[15] R. Hills,et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. , 2005, Blood.
[16] Ulrich Pohl,et al. Reactive Oxygen Species: Players in the Platelet Game , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[17] O. Sordet,et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes , 2000, Leukemia.
[18] G. Mufti,et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.
[19] T. Jacks,et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. , 2000, Molecular cell.
[20] Z. Estrov,et al. The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.
[21] P. Thall,et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] K. Calame,et al. Signaling Pathways Activated by Oncogenic Forms of Abl Tyrosine Kinase* , 1999, The Journal of Biological Chemistry.
[23] T. Naoe,et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.
[24] M MacFarlane,et al. Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis* , 1999, The Journal of Biological Chemistry.
[25] I. Weissman,et al. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] R. Darley,et al. RAS and the myelodysplastic syndromes. , 1997, Pathologie-biologie.
[27] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[28] D. Largaespada,et al. Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia , 1996, Nature Genetics.
[29] I. Weissman,et al. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages , 1994, The Journal of experimental medicine.
[30] I. Lemischka,et al. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells , 1993, Molecular and cellular biology.
[31] J. Magaud,et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.
[32] M. Barbacid,et al. ras gene Amplification and malignant transformation , 1985, Molecular and cellular biology.
[33] E. Scolnick,et al. Growth of factor-dependent hemopoietic precursor cell lines , 1980, The Journal of experimental medicine.